• TRADE NAME: Tudorza Pressair (Forest)
  • INDICATIONS: Long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema
  • CLASS: Anticholinergic, Muscarinic antagonist
  • HALF-LIFE: 5–8 hours
  • FDA APPROVAL DATE: 07/30/2012
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    Anticholinergics

Please login to view the rest of this drug profile.

Page last updated 07/31/2023

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric